Clever Culture Systems Ltd
16 Anster St
Adelaide SA 5000
www.cleverculturesystems.com

CLEVER CULTURE SYSTEMS

ASX:CC5

ADDITIONAL 4 APAS® INSTRUMENTS ORDERED BY ASTRAZENECA

Total contract value of additional order expected to be worth over AU$3.1 million[1]

Adelaide, Australia, 5 December 2024: Leaders in AI microbiology automation, Clever Culture Systems Ltd (ASX: CC5) (**CCS** or the **Company**) formally LBT Innovations (ASX: LBT), is pleased to announce the Company has received an order from AstraZeneca AB (**AstraZeneca**) for the purchase of four additional APAS® Independence instruments. The instruments are expected to be delivered in the current financial year, ending 30 June 2025, resulting in 100% of the revenue associated with the instrument sales being recognised. When including annual maintenance and support fees for each instrument, the order is expected to be worth over USD $2.0 million, equivalent to ~AU$3.1 million, over seven years[1].

Highlights:

- **Second order by AstraZeneca to purchase an additional 4 APAS® Independence instruments**
- **Increases AstraZeneca total commitments to 9 APAS® instruments, valued up to ~AU$7.2 million[1, 2]**
  - **First order of 5 instruments [Aug-24] now delivered to multiple AstraZeneca facilities globally**
  - **Second order of 4 instruments planned for delivery during first half of calendar year 2025**
- **New Contact Plate application adds further utility to APAS® Independence for environmental monitoring applications that supports the additional roll out by AstraZeneca**
- **12 APAS® Independence sales to pharmaceutical customers since product launch in Mar-24 underpins the potential for a cash flow positive result for full FY25**

Brent Barnes, CCS CEO & Managing Director said:

"We are pleased to have delivered the first five instruments to multiple AstraZeneca facilities over the past three months as planned. This additional order of four APAS® instruments allows expanded standardisation of APAS® to additional AstraZeneca global sterile drug manufacturing locations. The addition of contact plates to the APAS® platform was a key factor for this additional commitment of roll out, enabling AstraZeneca extended functionality to automate another test performed during route environmental monitoring.

We expect to complete the deliveries and installations in the first half of calendar year 2025 and look forward to continuing our collaboration with the AstraZeneca sites to embed the APAS® platform throughout their global network.

Karen Capper, Head of Microbiology, Science & Technology, AstraZeneca Pharmaceutical Technology and Development said:

"We are looking forward to standardising an important part of our environmental monitoring processes with APAS® Independence. The addition of the Contact Plate application is an important addition to the APAS® portfolio that increases the usefulness of the system for our laboratories globally. This was a key factor in our decision to extend our global roll out of the technology across our manufacturing network."

AstraZeneca global deployment expands to 9 APAS® Independence instruments

The Company has received an order from AstraZeneca for the purchase of four APAS® Independence instruments. The majority of the contract value is to be received as the four instruments are progressively delivered and installed, which is expected to be completed in the first half of calendar year 2025.

This order follows the previous purchase order of five APAS® instruments by AstraZeneca in August 2024 [ASX Announcement]. The five instruments associated with the initial order have now all been delivered as planned. These four additional APAS® instruments extend AstraZeneca's roll out of the technology across their manufacturing sites globally and brings the total instruments purchased by AstraZeneca to nine.

---

[1] Estimated contract value assumes the potential annual maintenance and support services. *USD:AUD 1.55*

[2] ASX:LBT Aug-24 announcement of 5 APAS® sales totalling up to AU$4.1 million + Nov-24 of 4 APAS® sales of $3.1 million, both including potential maintenance and support services for each instrument.

Clever Culture Systems Ltd
16 Anster St
Adelaide SA 5000
www.cleverculturesystems.com

CLEVER CULTURE SYSTEMS

ASX:CC5

It is expected that AstraZeneca will finalise their internal validation of APAS® for environmental monitoring and start progressively integrating APAS® Independence into routine operation for drug manufacturing over the coming months.

Addition of Contact Plate application to APAS® platform an important factor in AstraZeneca's purchase decision

In August, the Company announced a new development project to enhance the APAS® Independence platform with Contact Plate functionality [ASX Announcement]. This enhancement enables the APAS® instrument to process both 90mm settle plates and the smaller 55mm contact plates, including a new analysis module for the reading of environmental monitoring contact plates. As a result, customers can now process more of their environmental monitoring plates through each APAS® Independence instrument.

AstraZeneca has been a long-term development partner for the Company supporting the development of the APAS® Independence for pharmaceutical environmental monitoring applications. In October, the Company installed the new APAS® Contact Plate application on the AstraZeneca development instrument in the United Kingdom. The availability of this new module was an important factor for AstraZeneca to extend their global roll out of the APAS® technology across their network, ensuring the laboratories automate more tests for their environmental monitoring workflow.

Once the Contact Plate has been validated and rolled out across the AstraZeneca network, annual license fees will apply to the use of this new analysis module increasing the Company's annual recurring revenue on any of AstraZeneca's APAS® instruments.

Approved for release by the CCS Board.

– ENDS –

About Clever Culture Systems
Clever Culture Systems (CCS) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading. The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

Clever Culture Systems
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@cleverculturesystems.com